Esteffania Villegas-Santamaria, MD
Cardiovascular Disease · Ames, IANPI 1457804395
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,566 of the $2,031 with a category attached, or 77.1%. 15 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 26.4% of the total. Reporting peaked in 2021 at $665 and has fallen 97.3% since, to $18 in 2025.
Across 88 payments — averaging $23.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$536
- Novartis$277
- AstraZeneca$202
- Abbott$182
- Merck$160
- Amgen$112
- plus $562 from 9 others
What the payments were for
- Food & beverage$1,56677%
- Education$46523%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $536 |
| Novartis | 16 | $277 |
| AstraZeneca | 13 | $202 |
| Abbott | 3 | $182 |
| Merck | 9 | $160 |
| Amgen | 5 | $112 |
| Medtronic | 6 | $105 |
| Pfizer | 4 | $91 |
| Boehringer Ingelheim | 3 | $83 |
| E.r. Squibb & Sons, L.L.C. | 5 | $74 |
| Lantheus Medical Imaging, Inc. | 3 | $70 |
| Abiomed | 2 | $58 |
| Johnson & Johnson | 1 | $36 |
| Astellas Pharma US Inc | 1 | $23 |
| Boston Scientific | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,031 in reported general payments places this provider in the 60th percentile of 142 cardiovascular disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 133 | $120,520 |
| JardianceEmpagliflozin | 26 | $22,455 |
| XareltoRivaroxaban | 27 | $22,163 |
| EntrestoSacubitril/Valsartan | 19 | $20,500 |
| BrilintaTicagrelor | 19 | $19,965 |
| Metoprolol Succinate | 189 | $1,386 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 21 | $1,277 |
| Atorvastatin Calcium | 82 | $619 |
| Bumetanide | 22 | $511 |
| Potassium Chloride | 14 | $430 |
| Amiodarone Hcl | 57 | $360 |
| Amlodipine Besylate | 77 | $303 |
| Losartan Potassium | 46 | $287 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 23 | $275 |
| Rosuvastatin Calcium | 60 | $270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $91 | $120,520133 claims |
| Boehringer IngelheimJardiance | $83 | $22,45526 claims |
| Johnson & JohnsonXarelto | $36 | $22,16327 claims |
| NovartisEntresto | $277 | $20,50019 claims |
| AstraZenecaBrilinta | $202 | $19,96519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 142 cardiovascular disease providers in Iowa.
Other cardiovascular disease in Ames
- Brian OlshanskyIowa City$219K
- Troy HounshellWest Des Moines$164K
- Enrico MartinWest Des Moines$113K
- Gursukhman Deep SidhuDavenport$60K
- Suzanne FeigofskyWest Des Moines$59K
- Tyler RasmussenCedar Rapids$37K
- Jennifer RobinsonIowa City$37K
- Matthew McMahonCedar Rapids$35K
- Craig StarkDes Moines$28K
- Tauseef KhanDubuque$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.